SHINE Secures Another Supply Agreement

SHINE Medical Technologies has entered into a supply agreement with Lantheus Medical Imaging to provide the diagnostic imaging company with molybdenum-99, the medical isotope used in millions of procedures annually, the company announced this week. SHINE is one of several companies trying to get through the regulatory hurdles to begin the production of Moly-99, and it expects to start production by the end of 2017. This supply agreement marks the second such agreement SHINE has entered into. It previously announced an agreement to supply GE Healthcare as well. “This definitive agreement with Lantheus signals the beginning of a new era for the production of radioisotopes in North America, in which a private producer can thrive,” SHINE CEO Greg Piefer said in a statement. “This agreement, along with another agreement earlier this year, shows that SHINE is important to the future of medical isotope generation. We could not be more pleased that this agreement is with Lantheus — a long-time global leader in the production of Tc-99m generators, and a pioneer in the area of LEU-conversion. We look forward to serving their needs with our cost effective, safe, and environmentally-friendly production technology.”